Astria Therapeutics’ (ATXS) “Buy” Rating Reaffirmed at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 50.52% from the company’s previous close.

A number of other equities analysts have also weighed in on ATXS. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Oppenheimer increased their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Performance

Astria Therapeutics stock traded up $0.02 during midday trading on Thursday, hitting $10.63. 126,032 shares of the company’s stock were exchanged, compared to its average volume of 614,761. The stock has a market cap of $599.80 million, a price-to-earnings ratio of -4.53 and a beta of 0.71. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90. The firm’s 50 day simple moving average is $11.46 and its 200 day simple moving average is $10.61.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, equities research analysts forecast that Astria Therapeutics will post -1.68 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Walleye Capital LLC boosted its position in shares of Astria Therapeutics by 69.3% in the 3rd quarter. Walleye Capital LLC now owns 174,581 shares of the biotechnology company’s stock worth $1,922,000 after buying an additional 71,439 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Astria Therapeutics in the third quarter valued at about $613,000. FMR LLC grew its position in shares of Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Astria Therapeutics by 152.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock worth $3,460,000 after purchasing an additional 189,727 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $228,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.